Clinical application of AD-MSCs – A review

Ekaterina Semenova1, Magdalena Chroscinska-Krawczyk2, Mariusz Piotr Grudniak1, Tomasz Oldak1, Eugeniusz Krzysztof Machaj1

1 Polish Stem Cell Bank, Warsaw, Poland
2 Clinic of Paediatric Neurology, III Faculty of Paediatrics, Medical University, Lublin, Poland


Abstract
Introduction. Mesenchymal stromal/stem cells (MSCs) are a unique type of stem cell which can be successfully used in regenerative medicine. They are safe, have the ‘stem cell’ ability of self-renewal and under appropriate conditions can differentiate into other types of cells without the problem of teratoma formation. MSCs express the characteristic phenotype (CD73+, CD90+, CD105+, CD14−, CD19−, CD34−, CD45−, HLA-DR−) and show immunosuppressive features, such as low expression of MHC I, lack of MHC II and secretion of a wide variety of immunoprotective cytokines and growth factors. One of the MSC sources is adipose tissue, which has some advantages compared with other existing sources. Currently, adipose tissue as a source of mesenchymal stromal/stem cells have become of interest due to a less invasive procedure of isolation and safety. This review contains data from various studies about the usage of adipose-derived MSCs in the treatment of different diseases.

Objectives. The main aim of this review is evaluation of the useful characteristics of adipose-derived mesenchymal stem cells and their usage in stem cell treatment of some diseases. The aim is to describe the current knowledge and future perspectives.

Conclusions. Adipose-derived MSCs (AD-MSCs) represent a good tool in regenerative stem cell therapy.

Key words
adipose-derived mesenchymal stem cell (AD-MSC), stem cell therapy, regenerative medicine

INTRODUCTION

Mesenchymal Stem/Stromal Cells (MSCs) are widely used in the field of regenerative medicine, but their optimal source is still being sought. Friedenstein was the first to isolate and identify MSCs from bone marrow [1]. Later, MSCs were successfully isolated from a range of tissues and organs: adipose tissue, peripheral blood, amniotic fluid, placenta and umbilical cord [2, 3]. The bone marrow-derived MSCs are commonly used in clinics for many applications, including to stimulate growth in patients with osteogenesis imperfecta, repair of articular cartilage defects and prevent death from GVHD (Graft-versus-host disease) [4, 5, 6]. Another source of MSCs is adipose tissue. Isolation from this tissue has some important advantages compared to bone marrow: it is safer for the donor and less time consuming. The most widely used procedure to obtain adipose tissue is liposuction. According to the American Society for Aesthetic Plastic Surgery, liposuction was included in the top five surgical procedures in 2016 (Statistic Cosmetic Surgery National Data Bank Statistics 2016). Generally, liposuction is safe for the patient, less invasive and well tolerated. The cells can be isolated using special automated devices, e.g. SmartLipo™ (Cynosure Inc., Westford, MA, USA), MicroAire Surgical Instruments (Charlottesville, VA, USA) or protocol of manual isolation (Fig. 1) [7].

After liposuction, two cell populations are available:
• Stromal Vascular Fraction (SVF).
• Adipose-Derived Mesenchymal Stem/Stromal Cells (AD-MSCs).

SVF is a heterogeneous cell population which includes some blood cells (erythrocytes, monocytes), fibroblasts, smooth muscle cells, EPC (endothelial progenitor cells), pericytes and MSCs (Fig. 2) [8]. Therefore, SVF is characterized by...
the presence of CD34⁺, CD45⁺, CD73⁺, CD90⁺, CD105⁺ and other CD cell surface markers [9, 10]. SVF is rich in many growth factors: IGF-1 (Insulin-like growth factor 1), VEGF (Vascular endothelial growth factor), PDGF (Platelet-derived growth factor) and FGF (Fibroblast growth factor) [11]. In clinical application in which fast angiogenesis is important, SVF is used successfully [12, 13].

To isolate AD-MSCs, SVF is cultured under special conditions. AD-MSCs have a standard fibroblast-like form, are characterized by the presence of CD73⁺, CD90⁺, CD105⁺ and CD34⁺, CD45⁺, HLA-DR⁻ cells, and have the possibility to differentiate osteogenic, adipogenic and chondrogenic lineages (Fig. 3), which fulfills the minimal criteria of MSC established by the International Society of Cellular Therapy [9, 10, 14].

AD-MSCs have the ability (similar to SVF) to secrete various important factors, such as TNF-α (Tumour Necrosis Factor-alpha), TGF-β (transforming growth factor-beta), VEGF, HGF (Hepatocyte Growth Factor), and some interleukins. In 2004, Rehman et al. reported that AD-MSCs, under hypoxia condition, secrete a considerable amount of VEGF and HGF and induce healing in mice hindlimb ischemia [15]. The cytokines which AD-MSCs expressed affect the differentiation of these cells. VEGF and HGF increase the chondrogenic and hepatogenic differentiation of AD-MSCs in vitro, respectively [16, 17]. FGF promotes and increases adipogenic and chondrogenic differentiation in vitro, but blocks osteogenic differentiation, whereas EGF inhibits adipogenic differentiation [18].

According to Salgado et al., AD-MSCs demonstrated an immunomodulatory ability, which was closely connected with their secretome [19] (Fig. 4). Besides the immunomodulatory properties of MSCs, Spaeth et al. showed their capacity to migrate to sites of injury or inflammation [20].

**Figure 3.** AD-MSCs in culture. A – undifferentiated cells; B – adipocytes; C – chondrocytes; D – osteoblasts

**Figure 4.** Scheme of MSCs immunomodulation activity. MSCs inhibit proliferation and maturation of immune cells. They suppress immune reaction in vitro and in vivo

### USAGE OF AD-MSCS

**Wound healing.** Skin is a tissue with natural possibilities of self-repair after injury. Correct healing leads to repairing skin integrity and consists of a few stages: activation of cells (immune cells, fibroblasts, MSCs), proliferation of cells and skin remodeling (re-epithelialization). Methods of wound treatment include hyperbaric O₂ [21], various growth factors (FGF, EGF (epidermal growth factor), TGF-β, VEGF, SDF-1 (stromal cell-derived factor 1) [22, 23] and stem cell treatment.

Stem cell treatment appears to be most promising (Tab. 1). AD-MSCs are good candidates for wound treatment because they secrete many cytokines and growth factors which improve wound healing [24] and vascularization [25]. The Huang research group used the fourth passage with a high level of secretory protein expression (VEGF, HGF) [26]. They demonstrated immediate effects of AD-MSCs and/or paracrine activity in rat model in vivo. These effects were shown earlier

### Table 1. Properties of AD-MSCs useful for regenerative medicine

<table>
<thead>
<tr>
<th>Property in vivo</th>
<th>Study</th>
<th>Mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enhance angiogenesis</td>
<td>hSVF transplantation to mouse hind limb</td>
<td>Differentiation of endothelial cells</td>
<td>Nakagami et al., 2005</td>
</tr>
<tr>
<td>Wound healing promotion</td>
<td>rAD-MSCs in radiation ulcer of a rat model</td>
<td>Production of cytokines (SDF-1, VEGF, HGF)</td>
<td>Huang et al., 2013</td>
</tr>
<tr>
<td>Skin wound in rat model</td>
<td>Production of cytokines (VEGF, HGF) improve the cell proliferation and neovascularization</td>
<td>Sheng et al., 2013</td>
<td></td>
</tr>
</tbody>
</table>
by the Rehman group in mouse ischemia model in vivo [15]. Huang et al. also have shown that transplantation of AD-MSCs after culturing intensifies the process of wound healing due to the increase of blood supply and granulation rate. Huang also demonstrated that AD-MSCs were present in the injury area for 14 days, which suggests their long-term activity.

The use of auxiliary natural/synthetic components, such as fibroin–chitosan scaffold, collagen scaffold, cellular matrix scaffold, biopolymeric scaffold for local AD-MSCs treatment, probably improves the healing of wounds due to scaffold-mediated inductive processes (e.g. generation of bioactive peptides) [27, 28].

Kuo et al. reported that AD-MSCs can improve diabetic wound healing in an streptozotocin-induced animal model of diabetes [29]. Rats were treated subcutaneously in the diabetic inflammatory region with AD-MSCs (non-diabetic). In comparison with the control group, the group treated by AD-MSCs showed a reduced area of wound and improved angiogenesis.

At least three clinical studies with key words ‘wound heal’ and ‘AD-MSC’ were registered on clinicaltrials.gov (database as of 02.02.2018).

Regeneration of nerves. Injuries to peripheral nerves result in chronic pain and lead to disability in many patients. Using electrical stimuli, magnetic field and drugs increase nerve regeneration, and thanks to the progress in surgery in recent years recovery is improved. A promising option to regenerate nerves is stem cell-based therapy. Marconi et al. confirmed that AD-MSCs intravenously administered one week after sciatic nerve crush injury in a murine model of acute axonal damage, significantly increased functional recovery. Besides the decrease of inflammation, the authors suggested that AD-MSCs could produce some neuroprotective factors, e.g. FGF, IGF in mouse model of sciatic crush [30]. Another scientific group confirmed in a mice in vitro study that AD-MSCs express multiple genes necessary for the nerve growth and myelination [31]. The BDNF production by AD-MSCs stimulated nerve repair and growth.

Currently, studies based on the use of mesenchymal stem cells from different tissues, including MSCs from adipose tissue, are widely used. The easy access and possibility of autologous cell source make MSCs from adipose tissue more accessible than MSCs from any other sources. Intravenous administration of MSCs improves regeneration of the axons [32, 33]. The expression of special genes (peripheral myelin protein 22, myelin basic protein) by AD-MSCs is required for nerve repair and improves myelination.

Another method is the use of co-cultivation of AD-MSCs with Schwann cells to increase the efficiency of axon regeneration and improves neural differentiation [34, 35]. Schwann cells are the key player in nerve regeneration, but use of these cells is limited because of invasive procedure of isolation. AD-MSCs demonstrate successfully the differentiation into neuronal lineage and Schwann cells [36]. In addition, AD-MSCs can produce some neurotrophic factors, such as NGF (nerve growth factor) and BDNF [15, 30, 31]. The co-culture AD-MSCs with Schwann cells stimulates the AD-MSCs to differentiate into Schwann cells [37].

The method using AD-MSCs with growth factor TGF-β demonstrates that AD-MSCs are protected from apoptosis due to inflammation inhibition and enhancement of angiogenesis in vivo [38].

At least one clinical study with key words ‘nerve injury’ and ‘AD-MSC’ were registered on clinicaltrials.gov (database as of 02.02.2018).

Soft tissue reconstruction/craniofacial surgery. In reconstructive surgery, SVF and AD-MSCs are an important source due to their ability to stimulate angiogenesis, immunomodulation and multi-differentiation. Clinical therapies use the ability of AD-MSCs to differentiate chondrocytes, osteocytes and adipocytes for reconstructive surgery to repair cartilage, bone or soft tissue defects. The natural ability of AD-MSCs to differentiate chondrocytes is supported by a mixture of special ingredients and growth factors: TGFβ, dexamethasone and ascorbate. Some scientific groups which have used special culturing techniques and biomaterials (3D micromass culture, porous hyaluronic acid scaffold, fibrin glue scaffold, alginate microbeads, adding TGF-β) demonstrated improvement in the effectiveness of chondrogenic differentiation in vivo [39–44].

AD-MSCs were first used in 2004 in bone reconstruction [45]. AD-MSCs, in cooperation with autologous bone and fibrin glue, can stimulate new bone formation [46]. Using granules (β-tricalcium phosphate) and scaffolds helps bone repair [47, 48].

AD-MSCs have a high potential to differentiate into adipocytes and to promote angiogenesis [49]. Adding AD-MSCs to fat graft can increase the survival of transplanted cells [50]. Using a combination of an SVF population and adipose tissue produced better results in terms of transplant survival than using cells without SVF, as performed in 9 patients [51].

At least three clinical studies with key words ‘soft tissue defect’, ‘bone defect’ and ‘AD-MSC’ were registered on clinicaltrials.gov (database as of 02.02.2018).

Diseases affecting skin. Acne is a stressful, long-term skin disease. As described previously, AD-MSCs increase wound healing. Zhou et al. showed the effectiveness of conditioned media of MSCs derived from adipose tissue in the treatment of 13 patients with atrophic acne scars [52]. They observed increased hydration and skin elasticity, higher concentration of dermal collagen and higher elastin density. Due to their possibility to produce various growth factors, such as BFGF, KGF (keratinocyte growth factor), TGF-β1, HGF, VEGF, conditioned medium of AD-MSCs increases the production of dermal collagen and fibroblasts migration into the dermis, which can be used to decrease/eliminate wrinkles and even improve facial defects.

Injection of AD-MSCs to a dermal substitute improves human skin regeneration by increasing angiogenesis and collagen production [53]. In 2013, Salahat and Hadid noticed that using AD-MSCs in vivo caused the growth of human vascular endothelial cells, which promoted wound healing, generation of new blood vessels, and increased production of collagen and hyaluronic acid due to the synthesis of various growth factors described previously [54]. These two substances (collagen and hyaluronic acid) are also used in beauty injection therapy to treat some skin defects. Using AD-MSCs in combination with platelet-rich plasma (PRP) in atrophic scars treatment brought good results in human, such as the healing of acne pustules and elimination of hyperpigmentation [55]. After the second session of treatment, the acne scars were less visible. PRP rich in growth factors,
such as PDGF, VEGF, TGF-β, EGF, FGF, IGF-1, are required for skin regeneration and promotion of angiogenesis.

**Treatment of obesity.** The rate of obesity cases have risen dramatically in recent years. This is connected with a higher risk of metabolic diseases, such as diabetes, hyperlipidaemia or cardiovascular diseases. As a potential treatment, adipose-derived cell therapy has been suggested. Studies are underway to understand the role of adipose tissue and adipose stem cells in obesity and to find potential therapy targets.

Obesity causes an excess of chronic energy and lipid storage in white adipose tissue [56]. This results in an imbalance between two processes: lipogenesis and lipolysis. *In vitro* in hypoxic conditions, adipocytes secrete various inflammatory cytokines, e.g. TNFa, III, IL6, and others [57]. These cytokines affect necrotic cells to eliminate them and cause tissue inflammation. Moreover, obese AD-MSCs are defective in important functions, such as differentiation, immunomodulation, self-renewal capabilities and promotion of angiogenesis [58]. Additionally, adipose cells begin to possess insulin resistance and lead to different metabolic diseases.

Cao described angiogenesis as a therapeutic target for obesity and metabolic diseases [59, 60]. Angiogenesis is crucial for the whole organism processes of the formation of new blood vessels. Adipose tissue is one of the most vascularized tissue in the organism, and the development of adipose tissue depends on the continuous remodeling and development of vascularization [61]. High vascularization in brown adipose tissue increases metabolism by providing oxygen molecules. Supported by earlier studies, the identification of AD-MSCs as a part of the vasculature niche claims that adipocytes develop in close contact with blood vessels [62]. Under hypoxic conditions, expression of angiogenic factors in adipose tissue was changed by increasing the level of VEGF and leptin [63]. VEGF and IGF are angiogenic factors, and the lack of these factors may lead to endothelial cell apoptosis. One of the possible strategies may be the blockade of the function of these factors, which may lead to the regress of adipose vessels and fat reduction. Another promising way of obesity treatment is gene therapy. The use of nonviral nucleic acid transfer into human AD-MSCs as a new method of stem cell treatment, demonstrates the potential of therapy with modified stem cells [64].

It is crucial to find potential therapy targets in obesity disease, because defective AD-MSCs play an important role in the development of obesity diseases: insulin resistance, inflammation and metabolic disorders.

At one clinical study with key ords 'besity' and 'D-MSC' were registered on clinicaltrials.gov (database as of 10.02.2018).

**Concluding remarks.** With their unique possibilities, such as high proliferation potential, ability to secrete several growth factors and to differentiate at least into three cell lines, the use of AD-MSCs can significantly improve and increase the quality of regenerative processes or damaged tissue reconstruction.

The attractiveness of using these is also enhanced by the way of their isolation. The availability, safety and simplicity of isolation of AD-MSCs make it the preferred resource for preclinical and clinical studies. The adipose tissue as a primary material is collected by the classic method of liposuction, and the protocol for cell isolation is known. The procedure of liposuction has been improved over the years, making this process the most popular aesthetic procedure in the world. Another important fact is that AD-MSCs are autologous cells. Patients can use their own cells in a range of surgical procedures without any complication. Autologous cells from adipose tissue are recognized as an ideal filler for the soft tissue replenishment due to their properties, like biocompatibility, readily availability, among others.

It is also important to remember the fact that SVF is a mixture of different cells, not only stem cells. Multiple recent studies show that AD-MSCs secrete several factors that affect different cell populations, and it is probable that there are some factors, expressed by AD-MSCs which may influence on target cells, but are not detected by current techniques. The better understanding of these unknown factors changes and expands the standard approach to AD-MSCs application. Furthermore, the mechanism of AD-MSCs action is still debatable. Presumably, the clinical effect of AD-MSCs is a synergetic, more composite, and consists of the combination of differentiation and secreting ability.

To-date, more than 100 clinical studies using AD-MSCs have been registered. However, the difficulties with access to the results and the lack of systematic reporting of outcomes renders these therapies controversial and need much more evaluation.

**Acknowledgements**

This study was supported by Grant STRATEGMED2/267976/13/NCBR/2015 from the National Centre for Research and Development. The authors acknowledge the assistance of Magdalena Sendek, Mardin Mobasher and Anna Rożycka in reviewing the study.

**Abbreviations**

MSCs – Mesenchymal stromal/stem cells
MHC – Major histocompatibility complex
AD-MSCs – Adipose-derived mesenchymal stromal/stem cells
GVHD – Graft-versus-host disease
SVF – Stromal Vascular Fraction
EPC – Epithelial precursor cell
IGF-1 – Insulin-like growth factor 1
VEGF – Vascular endothelial growth factor
PDGF – Platelet-derived growth factor
TGF-β – transforming growth factor-beta
HGF – Hepatocyte Growth Factor
EGF – Epidermal growth factor
SDF-1 – Stromal cell-derived factor 1
BDNF – brain-derived neurotrophic factor
NGF – Nerve growth factor
KGF – Keratinoocyte growth factor
IL – Interleukin
PRP – Platelet-rich plasma

**REFERENCES**

65. Robey P. “Mesenchymal stem cells”: fact or fiction, and implications in their therapeutic use. F1000Research. 2017; 6(F1000 Faculty Rev): 524.